German pharmaceuticals and chemicals company Bayer AG says it plans a separate stock listing for...
The Department of Justice filed a court motion against the German conglomerate over its...
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an...
Bayer today announced the appointment of Malini Moorthy as Head of the Litigation Department in the United States, effective July 30. She succeeds Kaspar Stoffelmayr, whose three-year assignment ended and has rejoined Bartlit Beck Herman Palenchar & Scott LLP.
Compugen Ltd. has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare. The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen.
Bayer HealthCare LLC Animal Health is pleased to announce the launch of quellin (carprofen) soft chewable tablets to help alleviate the pain associated with canine osteoarthritis, one of the most common causes of chronic pain in dogs.
Bayer HealthCare announced today that the FDA has approved a new indication for Gadavist (gadobutrol) injection for intravenous use with MRI of the breast to assess the presence and extent of malignant breast disease.
In line with his own wishes, the contract of Dr. Marijn Dekkers will be extended by just two years on expiration of the initial five-year period. Dekkers cited family reasons for extending his contract only until the end of 2016.
In a move to expand significantly its portfolio of leading solutions for peripheral interventions, Boston Scientific Corporation has entered into a definitive agreement to acquire the Interventional Division of Bayer AG for $415 million in cash, including fees for transitional services.
By joining the portal, Bayer HealthCare is supporting efforts of the European Medicines Agency (EMA) to increase the transparency of data from clinical studies. As a member company of the pharmaceutical trade associations EFPIA and PhRMA, Bayer is following their declared principles on responsible clinical trial data sharing.
Bayer HealthCare announced today that the FDA has approved a new indication for Bayer's Kogenate FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.
Bayer AG says it plans to buy Merck's consumer care business, whose products include the Coppertone suncare range, Claritin allergy medicine and the Dr. Scholl's footcare products, for $14.2 billion.
A Washington University research project that provides free birth control to the poor and uninsured is under scrutiny for its off-label use of a contraceptive insert.
Bayer AG says its net profit jumped by almost a third last year to 3.19 billion euros ($4.35 billion) as sales hit a record high.
Bayer HealthCare Pharmaceuticals announced that its experimental, genetically engineered treatment for the most common type of bleeding disorder hemophilia met its main goal of reducing treatment frequency in a late-stage patient study.
Federal health experts are taking a second look this week at the heart safety of pain medications used by millions of Americans to treat arthritis and other everyday aches and pains. The Food and Drug Administration holds a two-day meeting starting Monday to examine the latest research on anti-inflammatory medicines called NSAIDS.
Bayer HealthCare to Invest in Manufacturing Operations as Next Step in Recent Animal Health Business AcquisitionJanuary 20, 2014 2:57 pm | News | Comments
Bayer HealthCare LLC has announced that the company will be improving efficiency and investing in its manufacturing operations in Missouri. The company will combine and transfer operations from three locations in the St. Joseph area to one beginning this year.
Regeneron Pharmaceuticals and Bayer HealthCare today announced an agreement to jointly develop an innovative antibody to the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) as a potential combination therapy with EYLEA (aflibercept) for the treatment of wet age-related macular degeneration (wet AMD).
Germany's Bayer AG is set to acquire cancer drug maker Algeta ASA after raising its offer for the Norwegian-based company to nearly $2.9 billion. The two firms said Thursday drug and chemical company Bayer will make a cash offer of 362 kroner ($59.24) per Algeta share.
Moberg Pharma AB has signed a deal to acquire three well established Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. Total annual sales for the brands are approximately 20 MSEK (ca 3 m$). The purchase price is 32 MSEK (4.8 m$) and is financed by available cash resources.
Norway-based cancer drug maker Algeta ASA says it has received a preliminary takeover offer from Germany's Bayer AG that values the company at about $2.4 billion. Algeta said in a statement Tuesday that the offer is for 336 kroner ($55.11) per share; the company has nearly 44 million shares.
The FDA has expanded approval of a Bayer drug to treat patients with thyroid cancer. Bayer's pill Nexavar is already approved to treat kidney cancer and liver cancer that cannot be surgically removed. Now the FDA has approved the drug to treat cancerous growth of the thyroid gland, which is located in the neck.
Drug and materials company Bayer AG says net profit rose 42 percent as sales increased for its new drugs aimed at preventing blood clots and treating the eye disease macular degeneration, while one-time expenses dropped. Net profit reached $1.01 billion.
Bayer HealthCare said Tuesday its drug Adempas has been approved as a treatment for two types of pulmonary hypertension, or high blood pressure in the arteries of the lungs. Bayer said it is already launching the drug, and called Adempas the first drug approved by the Food and Drug Administration...
Olivier Brandicourt has been appointed Chairman of the Board of Management of Bayer HealthCare and member of the Bayer AG Executive Council effective November 1, 2013. Since March 2013, Professor Wolfgang Plischke has led Bayer HealthCare on an interim basis in addition to his existing duties as a Bayer AG Board Member.
The pharmaceutical giant Bayer AG confirmed Friday that it is being investigated in China for possible unfair competition, making it the latest foreign drug maker to come under scrutiny in the country. The Germany-based company said it is cooperating with Chinese authorities in the investigation...
Onyx Pharmaceuticals and Bayer have announced that European Union regulators approved their pill Stivarga as a treatment for colorectal cancer. The companies said Stivarga was approved for the treatment of metastasized colorectal cancer in adults. In the U.S. Stivarga is approved as a treatment for...
The FDA granted priority review designation to a marketing application seeking approval of Bayer and Onyx Pharmaceuticals' Nexavar (sorafenib) for the treatment of locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer, the companies said Tuesday.
- Page 1